LYEL Stock Analysis: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$21.09
0.28 (1.35%)
▲
5d:
+4.3%
30d:
-11.39%
90d:
-31.48%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
LYEL is down 20.2% this week, but smart money is accumulating calls. Top strike: $27 2026-04-17 with 10 OI. Call ratio: 67% View Scanner →
Strength: 10.0/10
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LYEL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: LYEL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $21.09, which is considered fair relative to its 30-day fair value range of $19.93 to $23.94.
Technical Outlook: Technically, LYEL is showing sideways momentum. Immediate support is located at $17.34, while resistance sits at $22.00.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $32.50 (+56.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LYEL is showing sideways momentum. Immediate support is located at $17.34, while resistance sits at $22.00.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $32.50 (+56.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$19.93 -
$23.94
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 56.2% below Wall St target ($32.50)
Fair Price Analysis
30-Day Fair Range
$19.93 -
$23.94
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$17.34
Resistance Level
$22.00
Current Trend
Sideways
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.31
Wall Street Target
$32.50
(+56.2%)
Revenue Growth (YoY)
-45.5%
Share & Embed Analysis
Last updated: April 02, 2026 11:37 AM ET
Data refreshes hourly during market hours. Next update: 12:36 PM
Data refreshes hourly during market hours. Next update: 12:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Lynn Seely
SELL
7455 shares
2026-02-11
Stephen J Hill
SELL
1236 shares
2026-02-11
Gary K Lee
SELL
1671 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 56 HOLD |
